



# INTERMONTE November 29<sup>th</sup>, 2011

# **Company Presentation**



### **Disclaimer**

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.







- 2. EL.EN. GROUP
- 3. 9 M 2011 FINANCIAL RESULTS
- **4**. **2011 GUIDANCE**







## **The Global Laser Market**








### **LASER**

### Light Amplification Stimulated by Emission of Radiation

#### **LASER Sources**

(Laser beam generator)




### **LASER Systems**

(Manage laser beam energy to perform several applications)



## The Laser Market - Total: \$6.37 Billion



Industrial Processing \$ 2,2 B


Medical and Aesthetic \$ 0,45 B



### **El.En.: Trademarks and Markets**



### The MEDICAL Laser Market




Medical w\o diagnostic (Therapeutic) expected to grow to \$3,7B in 2014

El.En. medical revenues (FY2010) are 65% of consolidated sales



### The AESTHETIC Laser Market



- 1) Aesthetic products market (including cosmetics products) is expected to grow by 12.3% @ \$6.8 B
- 2) The skin tightening and body shaping systems market is expected to grow at the same rate, however average product prices are much higher in this segment.

Lumenis (Aesth)			
Cynosure (CYNO)(*)	2008	2009	2010
Cutera (CUTR)(*)	2000	2003	2010
Palomar (PMTI)(*)	\$ 860M	\$618M	\$683M
Syneron (ELOS) (*)			
Solta Medical (SLTM) (*)		-28%	+10%
El.En. (aesth w/o Cyno) (*)			



Source: Medical Insight Inc

(\*) Listed campanies

## The AESTHETIC Laser Market Shares

Revenues	in	\$	M
----------	----	----	---


El.En. Aesthetic/Medical Cynosure	2008 \$ 97.4 \$ 139.0	2009 \$ 72.8 \$ 72.5	2010 \$ 89.9 \$ 81.5
Peer group Total	\$ 860.7	\$ 617.7	\$ 683.7
% El.En.	11.3%	11.8%	13.1%
% Cyno	16.2%	11.7%	11.9%
% El.En. Group (*)	27.5%	23.5%	25.1%



### The INDUSTRIAL Laser Market

Laser Sources Market

Revenues (\$M)



#### Laser Systems Manufacturers Revenues (\$M)

	2008	2009	2010
Rofin Sinar	\$575	\$349	\$423
IPG	\$229	\$185	\$299
Coherent	\$599	\$435	\$605
Prima Industrie	\$477	\$300	\$325
Trumpf AG	\$2.161	\$1.742	\$2.631
Total	\$4.041	\$3.011	\$4.283
% YoY Change		-25,5%	42,2%
El.En. (industrial)	\$43	\$30	\$44





Source: Laser focus World

### **Strategic Strengths**

Multidisciplinary and multifacility R&D activity: sources, systems, applications.

Covering both Medical and Industrial laser markets

#### Industrial

✓ Combine High tech laser source development with flexible production facilities in high growth areas

#### Medical

- ✓ Maximize market penetration by multi brand approach
- ✓ Open new markets by developing new applications
- ✓ Leverage worldwide distribution











# El.En. Group









## **Group Overview**

#### High -Tech Industrial Group

Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications


Know-how based on 30 years stratification of multidisciplinary experience

Sept. 2011: Consolidated Revenues of €147 mln, up 9% YoY, 1.069 employees

Global positioning



### **Consolidated Revenues and EBIT**





### **R&D Activity**

Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser-tissue interaction

Laser systems for regenerative medicine

Laser and ultrasound combination systems for minimally invasive surgery

Development of new cutting edge CO<sub>2</sub> platform

High power surgical lasers

Integrated laser systems for skin ulcers treatment

Home use systems: Unilever project

Further improvements in laser lipolysis and cellulite treatment systems

Cutting and welding applications for 5 axes laser systems



# **R&D** expenses

	30/09/10	30/09/11	Var.%
R&D expenses	9,055	10,876	20.1%
Percentage on group revenues	7%	7%	
Grants	0,902	1,008	11.8%

- √ 100 Researchers
- ✓ 5 R&D labs:

Florence, Milan, Naples, Jena, Boston





## Medical/Aesthetic

#### Aesthetic

Hair Removal

Vascular Lesions

Skin Rejuvenation

**Pigmented Lesions** 

**Treatment of Cellulite** 

Acne

Tattoo Removal

Anti - Aging

LaserBody Sculpting

Removal of Unwanted Fat















#### Medical

**ENT** 

Gynaechology

Urology

Endovascular

Onchology

Dermatology

Psoriasis and Vitiligo

Dentistry

Therapy





# Cynosure

/ Be transformed			
	2002	70 % Acquisition	share price \$3,5
	2003-2004	Turnaround	
	2005	Nasdaq IPO, holding down to 35%	share price \$ 15
	2007	Stock sale, holding down to 23%	share price \$ 29
	2011	Eleme and ConBio acquisition	share price \$ 11
	Control and a	consolidation allowed by a statuto	ry clause



# **Cynosure**




### Strategic cooperation

R&D	Smartlipo MPX – Triplex - Cellulaze				
Distribution	Smartlipo - Fra	octional CO <sub>2</sub> – <sup>-</sup>	Γattoo Remov	val	
Sales of ex Cyno El.En. group to Cynosure (Euro 000)	2008 12,560	<b>2009 4,365</b>	<b>2010 4,167</b>	09/11 4,602	
% on ex Cyno Aesthetic sales	16.80%	7.80%	6.00%	9.70%	







## **Cynosure**











## 9 M 2011 Financial Results







## Consolidated P&L - 9 M 2011

83%	30/09/10 unaudited		30/09/11 unaudited		Var.%
Revenues	134.916	100,0%	147.330	100,0%	9,2%
Gross margin	72.261	53,6%	77.202	52,4%	6,8%
EBITDA	9.260	6,9%	7.853	5,3%	-15,2%
EBIT	2.833	2,1%	(65)	0,0%	
Income before taxes	1.685	1,2%	(768)	-0,5%	
	31/12/10		30/09/11		
Net financial position	74.900		42.669		



## Consolidated P&L - 9 M 2011 (w/o Cynosure)

	30/09/10		30/09/11		Var.%
	unaudited		unaudited		
Revenues	92.993	100,0%	97.718	100,0%	5,1%
Gross margin	47.248	50,8%	48.561	49,7%	2,8%
EBITDA	8.666	9,3%	7.599	7,8%	-12,3%
EBIT	5.354	5,8%	3.457	3,5%	-35,4%
Income before taxes	4.261	4,6%	2.795	2,9%	-34,4%
The same of the sa					
	31/12/10		30/09/11		
Net financial position	10.042		(3.826)		



## El.En. – Revenues breakdown by business





Service

Medical

Industrial

Medical
Aesthetic
Surgical CO<sub>2</sub>
Physiotherapy
Dental



September 30th 2010

September 30th 2011

Cynosure

Medical

Aesthetic Service 9M 2011: +5%



## El.En. - Medical and Aesthetic Sector



Industrial

Medical

Service

Accessories


Other Medical Lasers

Dental

Aesthetic

Physiotherapy

■ Surgical CO2



September 30th 2010

September 30th 2011

Cynosure

Medical
Aesthetic
Service

9M 2011: - 5%



### **El.En. – Industrial Sector**










Service Medical



September 30th 2010

September 30th 2011

Cynosure

Medical Aesthetic Service 9M 2011: +23%





# **2011 Guidance**









#### **INITIAL FORECAST:**

Sales + 10% EBIT% improvement

#### **UPDATED:**


H2 EBIT ≥ H1 EBIT (€3,2 Mln)




## El.En. and Cynosure stock performance

El.En

#### Cynosure







#### El.En. SPA

Enrico ROMAGNOLI

Investor Relations Manager

tel. +39 055-8826807

E-mail: finance@elen.it

#### POLYTEMS HIR SRL

Bianca FERSINI MASTELLONI

Financial Communication & Press office

Tel. +39 06-6797849 / +39 06-69923324

Empirical Computation States and in the machinists

E-mail: b.fersini@polytemshir.it

